Expansion of a US-headquartered gene therapy biotech into Europe.

Here’s how we strategically propelled AveXis’ expansion into Europe, helping them transition from clinical development into commercialization through the appointment of several senior hires across 7 European countries.

Permanent and contract placements
Director and associate director appointments
Days average time to hire
European territories covered

AveXis, a pioneering biotech company specializing in gene therapy and rare diseases, was on a mission to expand its clinical program throughout Europe with the end-goal of product commercialization. Under strict time constraints and with high stakes, they required candidates with niche skills to propel their growth and prepare for the commercialization of their lead product.

Problems identified

AveXis needed to quickly and strategically expand into Europe, a task complicated by the fast-tracked product designation, and the need for highly specific expertise in neuroscience, orphan disease drug development, and advanced therapy medicinal products for all their senior hires. With operations in the US and Switzerland, the firm looked to us to provide support for engaging and onboarding talent for their EU trials and commercial efforts.


What was at stake

The fast-tracked FDA and EMA applications meant strict time pressures applied to the project. Failure to establish their presence and recruit the right talent within the deadline could have severely hampered their growth and delayed their crucial clinical programme and subsequent commercial efforts


During a two year partnership, we made 36 crucial hires, including 8 director-level placements, 8 associate director-level placements, and several senior manager and manager-level placements. This strengthened AveXis' presence throughout the EMEA region, leaving to successful trial activities and eventual commercialization.



Our partnership resulted in the successful expansion of AveXis into Europe, and FDA and EMA approval of their lead product. Following the expansion, AveXis was acquired by Novartis, a testament to the success and value of their clinical and commercial program and acumen of the appointed senior leadership team.


Placement details.

During our partnership, we appointed 32 permanent members of the AveXis team, as well as four freelancers to support shorter-term projects and operations.

  • Senior Director, Spinal Muscular Atrophy
  • Director, Clinical Development
  • Medical Director, BeNeLux
  • Medical Director, France
  • Medical Director, Italy
  • Medical Director, Netherlands
  • Associate Director, Clinical Operations
  • Associate Director, Diagnostic Operations
  • Associate Director, Medical Information
  • Associate Director, Medical Information
  • Associate Director, Medical Information
  • Associate Director, Medical Information
  • Senior Manager, Clinical Trial Operations
  • Senior Manager, Clinical Trial Operations
  • Senior Manager, Medical Information
  • Senior Medical Manager, Gene Therapy
  • Manager, Clinical Operations
  • Regional Manager, Gene Therapy
  • Consultant, Clinical Development
  • Director, Business Operations
  • Director, Marketing and Market Research
  • Associate Director, Compliance
  • Associate Director, Regional Training
  • Senior Manager, Customer Services
  • Senior Manager, Procurement
  • Senior Manager, Sales Analytics
  • Manager, Customer Service 
  • Manager, Marketing Operations
  • Manager, Marketing Operations
  • Manager, Marketing Operations 
  • Manager, Pharmacovigilance Operations
  • Manager, Supply Chain and Distribution
  • Manager, Supply Chain, Artwork and Packaging
  • Executive Assistant
  • Executive Assistant

Build your own success story.

Allow us to support with your hiring requirements and scale as AveXis did. Get in touch with details about your current talent needs and let's build a winning strategy together.

Explore similar projects.

With fast-tracked designation for their lead product, AveXis required highly-skilled candidates with expertise in neuroscience and orphan diseases to lead their product to commercialization.

Read More

With a product launch imminent, fast-growing Swedish firm Acarix approached us to place two commercial leads within the DACH and US regions.

Read More

RVAC Medicines, a biotech firm specializing in mRNA technology, was embarking on an exciting journey to launch a new R&D facility in Boston—a previously unknown territory to them.

Read More
Copyright © All Rights Reserved SEC Life Sciences
Site by Venn